**Core tip:** By assessing patients with gastrointestinal neuroendocrine tumors from two independent United States claim databases, this study found that patients with carcinoid syndrome (CS) were 2-4 times as likely to have a preexisting diagnosis of a liver disorder, enlargement of lymph nodes, or abdominal mass than patients without CS.

INTRODUCTION
============

Neuroendocrine tumors (NETs), the most of common of which are carcinoid tumors\[[@B1]\], are characterized by a relatively indolent rate of growth and an ability to secrete a variety of peptide hormones. These tumors can be functional or non-functional and benign or malignant\[[@B1]\]. Even though NETs can develop anywhere in the body, the majority of them occur in the gastrointestinal (GI) tract (67.5%)\[[@B2]\]. Within the GI tract, sites of origin include the stomach, small intestine, appendix, and colorectum\[[@B2]\]. A 6-fold increase in the age-adjusted incidence of diagnosed NETs has been observed from 1.09 new cases per 100000 individuals in 1973 to 6.98 new cases per 100000 individuals in 2012\[[@B3],[@B4]\].

One of the more common functional NET syndromes is carcinoid syndrome (CS), occurring in 8% to 35% of NET patients\[[@B5]\]. CS occurs when functional carcinoid tumors metastasize to the liver or outside the GI tract, and the vasoactive hormones secreted by metastases, such as serotonin, histamine, or tachykinins, are no longer metabolized and inactivated by the liver and reach the general circulation\[[@B6],[@B7]\]. 5-hydroxyindoleacetic acid (5-HIAA), a product of serotonin metabolism of urinary excretion, is used as a first-line test for biochemical detection of suspected CS, in which 5-HIAA excretion is usually elevated\[[@B8]\]. CS includes an array of signs and symptoms. The classical manifestations of episodic flushing and diarrhea affect more than 80% of patients with CS\[[@B6]\]. Other signs include pellagra, wheezing, abdominal pain, telangiectasia and heart disease (usually right sided valvular regurgitation). The clinical presentation with diarrhea and/or abdominal pain dominating often leads to misdiagnosis of CS as irritable bowel disease or small bowel obstruction\[[@B9],[@B10]\] especially in middle-aged perimenopausal females. Delays in the correct diagnosis are common; reports on median time from onset of symptoms to diagnosis range from 2 to 20 years\[[@B9]\].

Other than the typical signs associated with CS, there is limited knowledge on the existence of any other predictors that may be associated with the risk of developing CS. We conducted the current study in patients with GI NETs, the most common type of NETs, to describe factors associated with CS with the intention of assisting physicians with making an earlier diagnosis of CS.

MATERIALS AND METHODS
=====================

Data source
-----------

We conducted a matched case-control study using data from two large United States healthcare claims databases - IMS PharMetrics Plus and Truven Health Analytics MarketScan. We used IMS PharMetrics Plus as the development database to derive risk factors for CS and MarketScan databases to validate the factors for CS. We used data from 1/1/2009 to 12/31/2014 from both databases.

The PharMetrics Plus database comprises adjudicated medical and pharmacy claims for approximately 150 million patients enrolled in United States health insurance plans, with an annual capture of 40 million. This database is representative of the United States commercially insured population for individuals under age 65 years. The MarketScan Research Database combines 2 separate databases-the Commercial Claims and Encounters database, and the Medicare Supplemental and Coordination of Benefits database. The commercial database contains the inpatient, outpatient, and outpatient prescription drug experience of about 40 million employees and their dependents, who are covered under a variety of fee-for-service and managed care health plans. The Medicare database contains the healthcare experience of about 3 million retirees with Medicare supplemental insurance paid for by employers. Both databases contain detailed cost, use, and outcomes data for inpatient and outpatient healthcare services. The medical claims are linked to outpatient prescription drug claims and person-level enrollment data through the use of unique enrollee identifiers. Both PharMetrics and MarketScan are Health Insurance Portability and Accountability Act compliant\[[@B11],[@B12]\]. The study was exempt from review by an institutional review board

Study population
----------------

The study population consisted of patients who were new diagnosed with GI NETs during the identification (ID) period (1/1/2010-12/31/2014). We identified patients with at least one inpatient or two outpatient claims with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for any NET (209.xx.) Among these, patients who had ICD-9-CM codes for GI NET (209.0, 209.1, 209.2, 209.4, 209.5, and 209.6) as the most frequent NET codes were classified as GI NET. To ensure that patients were newly diagnosed, we excluded patients with GI NETs during the 1-year prior to the first diagnosis date. We excluded patients with pancreatic NETs and Merkel cell carcinoma at any time during the study period.

We matched patients with GI NETs without CS (controls) to patients with CS (cases) based on the diagnosis date (month and year) of the first GI NET diagnosis at a 3-to-1 ratio. For cases, the index date was the first CS diagnosis date. For controls, the index date was assigned to have the same distance from the date of first NET diagnosis as the matched case patients. All patients were required to have at least 1-year continuous enrollment prior to the index date (study baseline).

The algorithm used to identify cases was developed based on a series of analyses performed before undertaking the main study. First, we examined overall prevalence of CS and the distribution of all NET locations (*e.g*., GI, lung, pancreas) in patients with a CS by identifying cases using a diagnosis (ICD-9-CM code 259.2) and found it did not match the expected distribution. Specifically, we found that 6% of patients with pancreatic neuroendocrine tumor (PNET) had at least two claims with a code for the CS, as did 23% of patients with GI NET. We suspected that the diagnosis code was being applied at an early point in the diagnostic process (*e.g*., as a "rule out"). We tested the application of more stringent criteria, which required two claims with ICD-9-CM code 259.2 and either a urine 24-h 5-HIAA \[Current Procedural Terminology (CPT) code: 83497\] or a serum serotonin (CPT code: 84260). In addition, the tests must have been ordered in the period 3 mo before or 3 mo after the CS diagnosis. This stricter algorithm resulted in only 1% of patients with PNET and 11% of GI NET being identified as having CS. As a result, we used the 2 CS diagnosis plus testing algorithm to identify cases with CS for this study.

Patient demographic characteristics included age in years on index date, sex, and geographic region (Midwest, Northeast, South, and West). Clinical characteristics included Charlson Comorbidity Index\[[@B13],[@B14]\], and number of chronic condition indicators \[[@B15]\].

The outcome of interest in this study was the presence of CS.

Statistical analysis
--------------------

We performed descriptive analyses to assess differences between case/control cohorts and patient demographic and clinical characteristics. χ^2^ tests were used for categorical variables and two sample *t*-tests were used for continuous variables.

Data mining is a process of selecting, exploring and modeling large amounts of data in order to discover unknown patterns or relationships that provide a clear and useful result\[[@B16]\]. We used data mining to explore unknown factors associated with CS. Specifically, using the development database (PharMetrics Plus), we assessed the top 50 most frequently observed conditions (based on CS patients) other than symptoms/diagnoses known to be associated with CS during the 1 year prior to the index date. We eliminated conditions or symptoms already known to be associated with CS, those related to screening or health maintenance, other GI cancers, and factors occurring in \< 10% of both case and control groups. We began the multivariate analysis by forcing demographics and two general comorbidity measures (Charlson Comorbidity Index and number of chronic conditions) into the model. We used forward-stepwise logistic regression to estimate, for each condition in the final model, the extent to which a patient who went on to be diagnosed with CS would have greater odds of having the condition than a patient who went on to be diagnosed with NET, but not CS. In the forward selection, significant factors (*P* \< 0.05) from the list of conditions referred to above were retained. Demographic or comorbidity measures were removed from the final model if they were highly insignificant (*P* ≥ 0.1). To validate these predictors, we re-ran the model with completely independent data from another administrative claims database (Truven MarketScan).

RESULTS
=======

Descriptive statistics
----------------------

Of the 23815 NET patients identified from the IMS PharMetrics Plus, the development database, we excluded 23310 patients who did not meet the inclusion criteria, such as enrollment, age, and definition of CS. Of the 505 patients who met the study selection criteria 251 were GI NET patients with CS (cases) (Figure [1](#F1){ref-type="fig"}). These 251 cases along with the 753 matched controls (GI patients without CS) were included in the final analytic sample in the development database. Case patients were slightly younger than control patients (mean ± SD: 52.8 ± 10.9 years *vs* 54.4 ± 13.3 years; *P =* 0.06). The majority of patients were in the 55-64 age range for both cohorts (37.5% in CS cohort; 34.1% in non-CS; *P =* 0.04). There were no significant differences in sex, region, and number of chronic conditions between the two cohorts (Table [1](#T1){ref-type="table"}).

###### 

Patient demographics *n* (%)

                   **Development Database**   **Validation Database**                                                                             
  ---------------- -------------------------- ------------------------- --------------- ----------- -------------- --------------- -------------- -------
  *n*              251                        753                       1,004                       181            543             724            
  Age (yr) 18-44   52.77 ± 10.88              54.37 ± 13.28             53.97 ± 12.74   0.058       51.76 ± 9.33   51.67 ± 10.03   51.69 ± 9.85   0.913
  52 (20.7)        143 (19.0)                 195 (19.4)                0.034           33 (18.2)   100 (18.4)     133 (18.4)      0.637          
  45-54            80 (31.9)                  219 (29.1)                299 (29.8)                  64 (35.4)      203 (37.4)      267 (36.9)     
  55-64            94 (37.5)                  257 (34.1)                351 (35.0)                  83 (45.9)      231 (42.5)      314 (43.4)     
  65+              25 (10.0)                  134 (17.8)                159 (15.8)                  1 (0.6)        9 (1.7)         10 (1.4)       
  Female           133 (53.0)                 407 (54.1)                540 (53.8)      0.770       109 (60.2)     297 (54.7)      406 (56.1)     0.195
  Region                                                                                0.306                                                     0.667
  Midwest          67 (26.7)                  219 (29.1)                286 (28.5)                  37 (20.4)      118 (21.7)      155 (21.4)     
  Northeast        57 (22.7)                  200 (26.6)                257 (25.6)                  41 (22.7)      100 (18.4)      141 (19.5)     
  South            106 (42.2)                 269 (35.7)                375 (37.4)                  80 (44.2)      254 (46.8)      334 (46.1)     
  West             21 (8.4)                   65 (8.6)                  86 (8.6)                    23 (12.7)      71 (13.1)       94 (13.0)      

![Patient identification. There were 23185 patients with at least one inpatient claim or two outpatient claims with selected NETs diagnosis (ICD-9-CM: 209.xx; excluding those for MCC) during the study ID period (01/01/2010-12/31/2014) in the development database. After excluding patients who were not newly diagnosed and did not have a NET diagnosis of interest; did not have 2 or more CS diagnosis during study period; did not have a 5-HIAA or blood serotonin test +/-90 days around their first CS diagnosis date (index date); were \< 18 years old; did not have CS diagnosis occurring after their first NET diagnosis; could not be matched; or were not continuously enrolled in the 1 year pre-index period, there remained 505 NET patients who met the study inclusion criteria. Out of these, 251 were GI NET patients with CS. GI NETs: Gastrointestinal neuroendocrine tumors; CS: Carcinoid syndrome; 5-HIAA: 5-hydroxyindoleacetic acid.](WJG-23-7283-g001){#F1}

In the validation database 724 patients with GI NETs were identified, among whom 181 (25%) had CS and 1158 (75%) were controls (Table [1](#T1){ref-type="table"}). The mean (SD) age in the CS cohort was 51.8 (9.33) years, compared to 51.7 (10.03) years in the non-CS cohort. There were no significant differences in age, sex, and region (Table [1](#T1){ref-type="table"}). With this approach, we identified a total of 33 most common conditions in both CS and non-CS cohorts (Table [2](#T2){ref-type="table"}) of the development database for further assessment. In both cohorts, abdominal pain (66.1% of CS cohort; 51.5% of non-CS cohort), hypertension (50.6%; 52.2%), and dyslipidemia (49.4%; 46.1%) were the most prevalent diagnoses (Table [2](#T2){ref-type="table"}).

###### 

Patients with gastrointestinal neuroendocrine tumors: Most frequent diagnoses1 in carcinoid syndrome patients, ordered by prevalence in carcinoid syndrome cohort *n* (%)

  **Diagnosis description**                                                                         **No. of patients**   **Difference in Rate** **(CS-Non-CS)**   **Relative Risk** **(CS *vs* Non-CS)**   
  ------------------------------------------------------------------------------------------------- --------------------- ---------------------------------------- ---------------------------------------- ------
  Abdominal pain[2](#T2FN1){ref-type="table-fn"}                                                    166 (66.14)           388 (51.53)                              14.61%                                   1.28
  Hypertension[2](#T2FN1){ref-type="table-fn"}                                                      127 (50.60)           393 (52.19)                              -1.59%                                   0.97
  Dyslipidemia[2](#T2FN1){ref-type="table-fn"}                                                      124 (49.40)           347 (46.08)                              3.32%                                    1.07
  Benign neoplasm large bowel                                                                       79 (31.47)            241 (32.01)                              -0.53%                                   0.98
  Esophageal reflux                                                                                 74 (29.48)            190 (25.23)                              4.25%                                    1.17
  Diverticulosis of colon (without mention of hemorrhage)                                           68 (27.09)            159 (21.12)                              5.98%                                    1.28
  Liver disorder[2](#T2FN1){ref-type="table-fn"}                                                    56 (22.31)            79 (10.49)                               11.82%                                   2.13
  Chest pain, unspecified                                                                           53 (21.12)            147 (19.52)                              1.59%                                    1.08
  Anemia, unspecified                                                                               51 (20.32)            141 (18.73)                              1.59%                                    1.09
  Pain in limb                                                                                      41 (16.33)            117 (15.54)                              0.80%                                    1.05
  Internal hemorrhoids without mention of complication                                              41 (16.33)            87 (11.55)                               4.78%                                    1.41
  Neoplasm of uncertain behavior of stomach, intestine, and rectum                                  39 (15.54)            95 (12.62)                               2.92%                                    1.23
  Nonspecific (abnormal) findings on radiological and other examination of gastrointestinal tract   38 (15.14)            66 (8.76)                                6.37%                                    1.73
  Lumbago                                                                                           38 (15.14)            79 (10.49)                               4.65%                                    1.44
  Enlargement of lymph nodes                                                                        36 (14.34)            40 (5.31)                                9.03%                                    2.70
  Malignant neoplasm of colon, unspecified site                                                     35 (13.94)            114 (15.14)                              -1.20%                                   0.92
  Hypothyroidism, unspecified                                                                       34 (13.55)            106 (14.08)                              -0.53%                                   0.96
  Abdominal or pelvic swelling, mass, or lump, unspecified site (begin 1994)                        34 (13.55)            60 (7.97)                                5.58%                                    1.70
  Other and unspecified noninfectious gastroenteritis and colitis                                   32 (12.75)            73 (9.69)                                3.05%                                    1.32
  Type 2 diabetes mellitus[2](#T2FN1){ref-type="table-fn"}                                          32 (12.75)            158 (20.98)                              -8.23%                                   0.61
  Other specified disorders of intestine                                                            29 (11.55)            70 (9.30)                                2.26%                                    1.24
  Obesity, unspecified                                                                              28 (11.16)            82 (10.89)                               0.27%                                    1.02
  Diaphragmatic hernia                                                                              28 (11.16)            65 (8.63)                                2.52%                                    1.29
  Headache                                                                                          28 (11.16)            74 (9.83)                                1.33%                                    1.14
  Anxiety state, unspecified                                                                        27 (10.76)            71 (9.43)                                1.33%                                    1.14
  Acute appendicitis, unspecified                                                                   26 (10.36)            91 (12.08)                               -1.73%                                   0.86
  Reflux esophagitis                                                                                26 (10.36)            41 (5.44)                                4.91%                                    1.90
  Abdominal or pelvic swelling, mass, or lump, other specified site                                 26 (10.36)            35 (4.65)                                5.71%                                    2.23
  Dyspepsia and other specified disorders of function of stomach                                    26 (10.36)            26 (3.45)                                6.91%                                    3.00
  Urinary tract infection, unspecified                                                              26 (10.36)            96 (12.75)                               -2.39%                                   0.81
  Pre-operative cardiovascular examination                                                          25 (9.96)             102 (13.55)                              -3.59%                                   0.74
  Tobacco use disorder                                                                              24 (9.56)             77 (10.23)                               -0.66%                                   0.94
  Constipation, unspecified                                                                         24 (9.56)             79 (10.49)                               -0.93%                                   0.91

^1^Claims in 1 year prior to the index date, excluding those for CS, NET, or symptoms/conditions known to be associated with CS;

Abdominal Pain (ICD-9-CM 789.0x, 789.6x); Type 2 DM (ICD-9-CM 250.x0, 250.x2); Hypertension (ICD-9-CM 401.xx, 402.xx, 403.xx, 404.xx, 405.xx, 437.2x); Dyslipidemia (ICD-9-CM 272.xx); Liver disorder (ICD-9-CM 573.8x, 573.9x). Variables not shown: Screening (Routine medical examination, Other screening mammogram, Long-term (current) use of other medications, Routine gynecological examination, Vaccination for influenza, Screen for malignant neoplasms of colon, Other specified pre-operative examination; GI cancer (Digestive neoplasm, unspecified); Prevalence \< 10% in both CS and non-CS cohort (Screening for malignant neoplasms of prostate, Backache unspecified, Other abnormal blood chemistry, Vitamin D deficiency unspecified, Lumbar or lumbosacral intervertebral disc degeneration, Atrophic gastritis without mention of hemorrhage, Personal history of colonic polyps, Cervicalgia, Iron deficiency anemia unspecified). CS: Carcinoid syndrome; NET: Neuroendocrine tumors.

Multivariable analysis
----------------------

Eight of the 33 common diagnoses tested remained significant in the forward step-wise logistic regression models and were further validated using the validation database (Table [3](#T3){ref-type="table"}). In the final, validated logistic regression model, three factors were associated with higher risks for CS, including liver disorder \[odds ratio (95%CI): 3.38 (2.07-5.51)\], enlargement of lymph nodes \[2.13 (1.10-4.11)\], and abdominal mass \[3.79 (1.87-7.69)\] (Table [4](#T4){ref-type="table"}).

###### 

Patients with gastrointestinal neuroendocrine tumors: Selected measures *n* (%)

                                                                   **Development database**   **Validation database**                                                                  
  ---------------------------------------------------------------- -------------------------- ------------------------- ------------ ---------- ------------ ------------ ------------ ----------
  *n*                                                              251                        753                       1004                    181          543          724          
  Abdominal pain                                                   166 (66.1)                 388 (51.5)                554 (55.2)   \< 0.001   104 (57.5)   253 (46.6)   357 (49.3)   0.011
  Dyslipidemia                                                     124 (49.4)                 347 (46.1)                471 (46.9)   0.361      67 (37.0)    209 (38.5)   276 (38.1)   0.724
  Diverticulosis of colon                                          68 (27.1)                  159 (21.1)                227 (22.6)   0.050      37 (20.4)    93 (17.1)    130 (18.0)   0.314
  Liver disorder                                                   56 (22.3)                  79 (10.5)                 135 (13.4)   \< 0.001   50 (27.6)    44 (8.1)     94 (13.0)    \< 0.001
  Enlarged lymph nodes                                             36 (14.3)                  40 (5.3)                  76 (7.6)     \< 0.001   23 (12.7)    25 (4.6)     48 (6.6)     \< 0.001
  Type 2 diabetes                                                  32 (12.7)                  158 (21.0)                190 (18.9)   0.004      30 (16.6)    91 (16.8)    121 (16.7)   0.954
  Abdominal mass                                                   26 (10.4)                  35 (4.6)                  61 (6.1)     0.010      23 (12.7)    16 (2.9)     39 (5.4)     \< 0.001
  Dyspepsia and other specified disorders of function of stomach   26 (10.4)                  26 (3.5)                  52 (5.2)     \< 0.001   8 (4.4)      35 (6.4)     43 (5.9)     0.318

CS: Carcinoid syndrome

###### 

Patients with gastrointestinal neuroendocrine tumors: Results of final model

  **Independent variable[1](#T4FN1){ref-type="table-fn"}**         **Development database**   **Validation database**                       
  ---------------------------------------------------------------- -------------------------- ------------------------- ------------------- ----------
  Age group                                                                                                                                 
  18-44 *vs* 65+                                                   2.30 (1.26-4.23)           0.007                     4.88 (0.56-42.11)   0.150
  45-54 *vs* 65+                                                   1.94 (1.14-3.31)           0.015                     3.63 (0.43-30.41)   0.235
  55-64 *vs* 65+                                                   2.01 (1.20-3.38)           0.008                     3.85 (0.46-31.93)   0.212
  Number of chronic conditions                                     0.94 (0.87-1.01)           0.093                     1.13 (1.02-1.24)    0.014
  Abdominal pain                                                   1.50 (1.08-2.09)           0.016                     1.22 (0.83-1.77)    0.309
  Dyslipidemia                                                     1.52 (1.08-2.15)           0.016                     0.83 (0.55-1.25)    0.373
  Diverticulosis of colon                                          1.55 (1.08-2.24)           0.019                     1.16 (0.72-1.86)    0.537
  Liver disorder[2](#T4FN2){ref-type="table-fn"}                   2.12 (1.40-3.20)           \< 0.001                  3.38 (2.07-5.51)    \< 0.001
  Enlarged lymph nodes                                             2.33 (1.38-3.92)           0.001                     2.13 (1.10-4.11)    0.025
  Type 2 diabetes                                                  0.59 (0.38-0.92)           0.021                     0.89 (0.54-1.48)    0.653
  Abdominal mass                                                   1.89 (1.06-3.37)           0.031                     3.79 (1.87-7.69)    \< 0.001
  Dyspepsia and other specified disorders of function of stomach   2.95 (1.60-5.43)           \< 0.001                  0.54 (0.23-1.26)    0.154

Variables found consistently significantly associated with risk of CS are bolded;

Liver disorder includes other specified disorders of liver (ICD-9-CM 573.8x, 573.9x). CS: Carcinoid syndrome.

DISCUSSION
==========

By assessing patients from two independent United States claim databases, this study suggested that in patients with proven GI NETs, patients with CS were 2-4 times as likely to have a preexisting diagnosis of a liver disorder, enlargement of lymph nodes, or abdominal mass than patients without CS.

Among patients with NETs, preexisting enlarged lymph nodes, abdominal mass lesions, and a liver disorder seem to jointly indicate increasing tumor burden, which implies that tumor progression may be associated with a higher risk of developing CS. Although there is no obvious clinical explanation for these findings, we propose the following two considerations: first, patients with CS have a larger systemic tumor bulk at diagnosis than patients who do not manifest CS, implying that increasing tumor burden correlates with increasing tumor products, which in turn led to the syndrome; and second, that patients with CS have more aggressive tumors than those without CS, which leads to more rapid growth of tumor and a larger burden of disease when diagnosed. The first consideration appears less likely since patients with small strategically located tumors (*e.g*., the ovary or lung) commonly present with CS prior to large bulky liver disease developing. On the other hand, it is well known that patients with CS have a poorer quality of life and outcome than those without CS suggesting that the latter explanation is more likely. To the best of our knowledge, this is only the second study assessing distinctions between CS and non-CS patients. The only other study we could identify in the existing literature is a recent study by Halperin and colleagues\[[@B17]\] that used SEER-Medicare data to assess the clinical factors that may be associated with CS specifically. They found that their CS cohort included more patients with regional and distant metastases, while their non-CS cohort included more patients with local disease; for each distinct site of tumor origin, the percentage of CS increased with tumor progression. In the aforementioned study, CS was also associated with shorter survival compared without patients without CS, further supporting the second explanation for our findings\[[@B17]\]. Of note, our findings extend Halperin's data in that we have now identified three specific predictors of the CS that can be used to direct physicians to specifically consider CS over a more general diagnosis of NET, and to monitor those patients more closely by 5-HIAA or serum serotonin testing In our study, we matched the CS and non-CS cohorts on duration of disease as carefully as possible, knowing that one of the limitations of using claims databases for research is that the precise diagnosis date is not the true date of tumorgenesis. Consequently the duration between the first NET diagnosis and first CS diagnosis was the best proxy for disease duration that we could use. Conditional on the reliability of this proxy, our findings suggest that patients who were eventually diagnosed with CS tended to have additional diagnoses indicating tumor advancement, compared with the non-CS patients who had the same duration of disease.

In general, early diagnosis of cancer can improve quality of life and survival\[[@B18]\]. Patients with CS have a significantly worse quality of life than patients with NETs but without CS\[[@B19]\]. Therefore, reducing delays in diagnosis may help improve quality of life in CS. In addition, our findings indicate that the poorer quality of life among patients with CS may also be a composite result of both tumor progression and CS symptoms, as the CS patients also tended to have more advanced tumor. Therefore, therapy for CS patients should address both symptom control as well as tumor progression to maintain quality of life.

In addition, we find it rather curious that there were no gender differences in our study. Since flushing is a common symptom of the CS, and since flushing is often confused with the hot flashes of menopause, one might have expected males with CS to be diagnosed earlier than females if the propensity is to misdiagnose CS until the disease is well established (with a known liver disorder, abdominal mass or lymphadenopathy). On the other hand, the delay in identifying CS in NET patients may simply be because flushing is not often sought out by physicians when interviewing patients. Indirectly then, these data suggest that educating physicians about the unusual manifestation of CS may help lead to an earlier diagnosis. The gender equivalence in our study may also be evidence that our algorithm for identifying CS, which required the presence of 5-HIAA or serotonin test around the diagnosis date, was reasonably specific for the condition, so that we minimized the misdiagnosed CS in our CS cohort by requiring this criterion for diagnosis.

Our study had limitations. First, GI NET and CS diagnoses were identified from healthcare claims coded for reimbursement, not research, and misclassification was possible. Errors in coding could bias our analysis. Specifically, patients with CS who have less severe symptoms may never be coded as having the syndrome. Nevertheless, health insurance claims data remain a valuable source of information as they constitute a fairly valid, large sample of patient characteristics and outcomes in a real-world setting. A strength of this study was that it was drawn from two very large underlying databases covering nearly 200 million patients enrolled in United States health insurance plans. The rate of CS among GI-NET patients in our study was higher than in some prior studies\[[@B20]\], and it was lower than at least one other\[[@B17]\]. The criteria we used to identify CS were more restrictive than the study by Halperin et al\[[@B17]\]. Current recommendations for diagnosing CS include measuring 5-HIAA\[[@B1],[@B21]\]. We incorporated that recommendation into our identification algorithm, requiring two claims with an ICD-9-CM code for CS and a claim for either a urine 24-hour 5-HIAA or a serum serotonin in the period surrounding that diagnosis, whereas the prior study required two claims for CS, diarrhea, or flushing. Second, because ICD-9-CM codes may be inaccurate, we were not able to identify the specific anatomic location (*e.g*., portion of large or small bowel) of the GI NET in our study. This could lead to confounding. For instance, small bowl NETs are more commonly associated with CS than large bowel tumors, and previous studies have suggested that hepatic and lymph node metastasis are usually present at time of small bowel NET diagnosis\[[@B22]\]. If our CS cohort systematically includes more small bowel patients than the non-CS cohorts, and the small bowel patients tend to be more advanced at diagnosis, this could explain why we see that CS patients were more likely to have this diagnosis. However, due to the lack of specificity of ICD-9-CM codes, we cannot confirm the anatomic section of the GI tract in which the tumor was identified. Therefore, we could not validate if small bowel NETs may present at a more advanced stage than other NETs based only on the data from a claims database. A study in a data source where the exact location of the tumor could be identified with confidence would be very useful to confirm our findings. Third, our results are reflective of a commercially-insured population, but may not be generalizable to patient populations with other insurance types.

In summary, our study suggests that a liver disorder, enlargement of lymph nodes, or an abdominal mass is associated with higher risk of a future CS diagnosis. There are two aspects with regards how this finding may be applicable to a real world clinical setting. First, CS develops insidiously, and patients who grow accustomed to their syndromic features such as flushing may not think of reporting these symptoms, even when prompted. If physicians are not aware of the presence of CS symptoms in their patients, our findings offer additional signs to prompt them to inquire specifically. Second, patients with a liver disorder, enlarged nodes, or abdominal mass may also not yet have clinically detectable CS symptoms, but may be destined to develop them in the future. In this context, our data suggest that in a patient with NET, even in the absence of typical symptoms, if one of these three findings is noted, consideration should be given to ordering a 5-HIAA or serotonin level. Although validation studies using patients' medical charts are warranted, such a practice could potentially aid physicians in speeding the diagnosis of CS.

ATRICLE HIGHLIGHTS
==================

Research background
-------------------

Functional neuroendocrine tumors (NETs) have the ability to secrete hormones that may cause carcinoid syndrome (CS), the most common symptoms of which include flushing and diarrhea. Carcinoid syndrome occurs in 8% to 35% of NET patients. Delays in diagnosis of CS are common, ranging from 2 to 20 years. Little is known about predictors that might be related the risk of developing CS.

Research motivation
-------------------

Patients with CS often face delays in getting the correct diagnosis. Their symptoms, such as diarrhea, are often mistaken for other diseases, such as irritable bowel disease. Finding risk factors that are associated with CS might help physicians with making an earlier diagnosis of CS.

Research objectives
-------------------

The objective was to identify risk factors that are associated with a future CS diagnosis.

Research methods
----------------

The authors conducted the study using data from two large United States health insurance claims databases. These databases contain healthcare cost, use, and outcomes data for covering nearly 200 million insured Americans. We first identified patients newly diagnosed with gastrointestinal NETs between 2010 and 2014 and then compared patients with CS to those without CS. We performed statistical analyses to identify the risk factors associated with CS from one databased and then validated the results using the other database.

Research results
----------------

The authors identified 251 patients with CS and 753 without CS in one database, and 386 patients with CS and 1158 patients without CS in the other database. There were no significant differences in age, sex, and region between patients with CS and those without CS. In both databases, we found that CS patients were 2-4 times more likely than non-CS patients to have a diagnosis of liver disorder, enlargement of lymph nodes, or abdominal mass within 1 year prior to their CS diagnosis.

Research conclusions
--------------------

This study suggests that diagnosis codes of liver disorder, enlargement of lymph nodes, or an abdominal mass are associated with higher risk of a future CS diagnosis. In a patient with NETs, even in the absence of typical symptoms, if one of these three conditions is noted, consideration should be given to ordering a test for CS. Such a practice could potentially aid physicians in speeding the diagnosis of CS.
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